Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

作者: Thomas G. Johnson , Karin Schelch , Sunali Mehta , Andrew Burgess , Glen Reid

DOI: 10.3389/FCELL.2019.00221

关键词:

摘要: Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates all cancer types, primarily due to a lack effective treatment options for most patients. Targeted therapies shown promise in thoracic cancers, although efficacy is limited only patients harboring specific mutations or target expression. Although number actionable now been identified, large population no therapeutic outside first-line chemotherapy. It therefore crucial identify alternative targets that might lead development new ways treating diagnosed with these diseases. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) could serve as one such target. Recent studies also link this protein many inherent behaviors cells proliferation, invasion, metastasis involvement stem-like cells. Here, we review regulation YB-1 at transcriptional, translational, post-translational sub-cellular levels discuss its potential use biomarker

参考文章(244)
Takashi Iwanami, Hidetaka Uramoto, Makoto Nakagawa, Hidehiko Shimokawa, Sohsuke Yamada, Kimitoshi Kohno, Fumihiro Tanaka, Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma. Oncology. ,vol. 86, pp. 109- 116 ,(2014) , 10.1159/000356874
Sarah Seton-Rogers, Therapeutics: siRNAs jump the hurdle. Nature Reviews Cancer. ,vol. 12, pp. 376- 377 ,(2012) , 10.1038/NRC3281
Frank Tacke, Oliver Galm, Nicolas Kanig, Eray Yagmur, Sabine Brandt, Jonathan A Lindquist, Christiane S Eberhardt, Ute Raffetseder, Peter R Mertens, High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin. BMC Cancer. ,vol. 14, pp. 33- 33 ,(2014) , 10.1186/1471-2407-14-33
Annette Lasham, Cristin G. Print, Adele G. Woolley, Sandra E. Dunn, Antony W. Braithwaite, YB-1: oncoprotein, prognostic marker and therapeutic target? Biochemical Journal. ,vol. 449, pp. 11- 23 ,(2013) , 10.1042/BJ20121323
Ulrike Stein, Karsten Jürchott, Wolfgang Walther, Stephan Bergmann, Peter M. Schlag, Hans-Dieter Royer, Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. Journal of Biological Chemistry. ,vol. 276, pp. 28562- 28569 ,(2001) , 10.1074/JBC.M100311200
PAUL ZAROGOULIDIS, SOFIA LAMPAKI, J. FRANCIS TURNER, HAIDONG HUANG, STYLIANOS KAKOLYRIS, KONSTANTINOS SYRIGOS, KONSTANTINOS ZAROGOULIDIS, mTOR pathway: A current, up-to-date mini-review (Review) Oncology Letters. ,vol. 8, pp. 2367- 2370 ,(2014) , 10.3892/OL.2014.2608
Ekaterina R Kim, Anastasia A Selyutina, Ilya A Buldakov, Valentina Evdokimova, Lev P. Ovchinnikov, Alexey V. Sorokin, The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress. Cell Cycle. ,vol. 12, pp. 3791- 3803 ,(2013) , 10.4161/CC.26670
Yi Shu, Fengmei Pi, Ashwani Sharma, Mehdi Rajabi, Farzin Haque, Dan Shu, Markos Leggas, B. Mark Evers, Peixuan Guo, Stable RNA nanoparticles as potential new generation drugs for cancer therapy Advanced Drug Delivery Reviews. ,vol. 66, pp. 74- 89 ,(2014) , 10.1016/J.ADDR.2013.11.006
Takefumi Ohga, Takeshi Uchiumi, Yoshinari Makino, Koji Koike, Morimasa Wada, Michihiko Kuwano, Kimitoshi Kohno, Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene Journal of Biological Chemistry. ,vol. 273, pp. 5997- 6000 ,(1998) , 10.1074/JBC.273.11.5997